Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Open Source Software
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
Is protracted low-dose temozolomide feasible in glioma patients?
Taming glioblastoma by targeting angiogenesis: 3 years later.
Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation.
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.
Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas.
Alternating Electric Fields Therapy for Malignant Gliomas: From Bench Observation to Clinical Reality.